Conquering Diseases

Study Of An Investigational Drug Added To Standard Chemotherapy For Pancreatic Cancer

Description

Seeking men and women with locally advanced pancreatic cancer that can't be completely removed with surgery for a study of an investigational drug added to the standard chemotherapy.

Overview

We are studying an investigational drug to reduce connective tissue growth factor (CTGF). Connective tissue growth factor (CTGF) is a protein naturally made in the body. If someone's body makes too much CTGF it may allow tumors to grow and spread. All study participants will receive the standard chemotherapy, but some will be randomly selected to also receive the investigational drug.

What we're hoping for

Evaluate whether adding an investigational drug to standard chemotherapy for locally advanced pancreatic cancer that can't be completely removed with surgery improves outcomes better than standard chemotherapy alone.

Additional Information

ClinicalTrials.gov Identifier: NCT03941093

 Principal Investigator

Venu G Bathini, MD

UMass Memorial Health Care

 Study Contact

The Cancer  Research Office

508-856-3216

Cancer.research@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989